Abbott Laboratories (NYSE:ABT) Analysts Show Growing Optimism

• Abbott Laboratories' consensus price target has increased to $147, indicating a positive outlook from analysts.
• The company's advancements in medical devices and diagnostics, especially during the COVID-19 pandemic, have boosted analyst confidence.
• Abbott's FreeStyle Libre CGMs and EPD business are expected to drive a 15% CAGR in sales by 2028.

Abbott Laboratories (NYSE:ABT) is a global healthcare company with a diverse portfolio that includes Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company has a strong presence in the healthcare sector, which has contributed to a positive sentiment among analysts. Over the past year, the consensus price target for Abbott has increased from $126.59 to $147, indicating growing optimism about its stock performance.

The company's advancements in medical devices and diagnostics, especially during the COVID-19 pandemic, have played a significant role in shaping analysts' positive outlook. Abbott's efforts in developing rapid diagnostic tests and other healthcare solutions have been well-received, further boosting confidence in its ability to innovate and perform well in the industry. This optimism is reflected in the steady consensus price target of $147 over the past month.

As Abbott prepares to announce its second-quarter earnings on July 17, 2025, analysts and investors are eagerly awaiting insights into the company's financial performance and future outlook. Analyst Marie Thibault from BTIG has set a price target of $130 for Abbott, suggesting a positive outlook for the company's stock performance. The upcoming earnings release is expected to provide valuable information on Abbott's growth prospects.

Abbott's FreeStyle Libre continuous glucose monitors (CGMs) and its Established Pharmaceuticals Division (EPD) business are driving positive momentum for the company. Key collaborations have expanded Abbott's global presence, making its CGMs more accessible to new patients. This expansion is expected to result in a compound annual growth rate (CAGR) of 15% in FreeStyle Libre sales by 2028, further supporting the positive sentiment among analysts.

Abbott's financial health is highlighted by its excellent balance sheet and a remarkable track record of over 50 consecutive years of dividend increases. This makes it an attractive long-term investment for income investors. The company's acquisition of rights to four more biosimilar products and a double-digit CAGR in target biosimilar emerging markets suggest that the EPD business could stimulate earnings per share (EPS) growth beyond its Medical Devices segment. Analyst Marie Thibault's price target of $130 reflects confidence in Abbott's growth prospects.